[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[e-drug] Tighter controls on drugs firms in China


  • From: "Wilbert Bannenberg" <wjb@wxs.nl>
  • Date: Wed, 9 Apr 2008 11:00:56 +0200

E-DRUG: Tighter controls on drugs firms in China
------------------------------------------------

[Here is an article that has been published in China Daily on 9 April 2008.
It addresses the drug issue in China. Note that as per the new changes in
ministries in China, SFDA is now back under the control of MOH. Copied as
fair use. WB]

Tighter controls on drugs firms

By Shan Juan (China Daily)
Updated: 2008-04-09 09:33

Measures will be introduced before the end of the year to better control the
supply of ingredients for medicines, especially those produced by chemical
firms that have crossed over into the drugs market, Yan Jiangying,
spokeswoman for the State Food and Drug Administration (SFDA), said
yesterday.

The image of China's pharmaceutical industry overseas has been tarnished by
a number of incidents involving unregistered companies, she said.

To redress the situation, the SFDA will introduce higher standards for
companies involved in the production of ingredients for pharmaceuticals, Yan
said.

As well as the new standards, greater efforts will be made to monitor
chemical firms that use regulatory loopholes to enter the pharmaceutical
ingredients market.

Several government agencies including the SFDA, the National Development and
Reform Commission and the new Ministry of Environmental Protection (MEP)
will be involved, she said.

The MEP will help weed out chemical firms that fail to meet environmental
protection standards, she said.

"Firms that do not have a permit from the SFDA to produce drugs or drug
ingredients are strictly prohibited from conducting any drug-related
business," Yan said.

Currently, only approved pharmaceutical companies are regulated by the SFDA,
while chemical firms are supervised by other agencies.

The problem arises when chemical firms make drug ingredients illegally.

"We have never investigated a chemical firm, as it's beyond our scope," Yan
said.

An industry insider said: "Some companies don't have the resources or means
to produce medicines. The bar for producing chemicals is pretty low."

Also, the large number of chemical plants in China, officially estimated at
about 80,000, makes the monitoring process more difficult, the insider said.

Despite the difficulties, the government is carrying out a nationwide
inspection to find out how many firms are involved in the drugs business,
Yan said.

In the long term, the SFDA will include all drug ingredients within its
identification and supervision system, she said.

"This will help us to monitor all aspects of the drug production process and
ensure drug safety," she said.

Currently, only selected high-risk drugs such as narcotics are covered by
the system. But by the end of October, it will be expanded to include blood
products, vaccine and traditional Chinese medicines that are taken
intravenously, she said.

Meanwhile, following a nationwide anti-doping campaign, 18 drug companies
and 14 drug retailers have been punished for illegally producing and selling
anabolic agents and peptide hormones, Yan said.